Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells $37,279.55 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Peter Heerma sold 1,771 shares of Travere Therapeutics stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total transaction of $37,279.55. Following the sale, the insider now owns 128,215 shares in the company, valued at approximately $2,698,925.75. The trade was a 1.36 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Peter Heerma also recently made the following trade(s):

• On Tuesday, February 11th, Peter Heerma sold 3,074 shares of Travere Therapeutics stock. The shares were sold at an average price of $25.00, for a total transaction of $76,850.00.

Travere Therapeutics Stock Up 1.2 %

Shares of Travere Therapeutics stock opened at $21.41 on Tuesday. Travere Therapeutics, Inc. has a 52-week low of $6.01 and a 52-week high of $25.29. The firm's 50 day moving average price is $18.09 and its 200-day moving average price is $18.77. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The company has a market cap of $1.90 billion, a P/E ratio of -5.22 and a beta of 0.88.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The firm had revenue of $81.73 million for the quarter, compared to the consensus estimate of $77.44 million. During the same period in the previous year, the business earned ($1.76) EPS. The firm's revenue for the quarter was up 83.3% on a year-over-year basis. On average, sell-side analysts predict that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TVTX has been the subject of a number of research reports. Canaccord Genuity Group increased their price target on Travere Therapeutics from $45.00 to $47.00 and gave the company a "buy" rating in a research note on Thursday, April 10th. Citigroup upped their price target on shares of Travere Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Monday, February 24th. Stifel Nicolaus lifted their price objective on shares of Travere Therapeutics from $22.00 to $23.00 and gave the stock a "hold" rating in a research note on Friday. JPMorgan Chase & Co. lifted their price target on Travere Therapeutics from $42.00 to $44.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $30.00 price objective on shares of Travere Therapeutics in a research note on Friday. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, Travere Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $31.79.

Institutional Investors Weigh In On Travere Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Entropy Technologies LP purchased a new stake in shares of Travere Therapeutics in the fourth quarter worth about $214,000. US Bancorp DE boosted its stake in shares of Travere Therapeutics by 323.4% during the 4th quarter. US Bancorp DE now owns 31,795 shares of the company's stock worth $554,000 after acquiring an additional 24,286 shares in the last quarter. Swiss National Bank grew its holdings in Travere Therapeutics by 12.8% in the fourth quarter. Swiss National Bank now owns 151,900 shares of the company's stock valued at $2,646,000 after purchasing an additional 17,200 shares during the period. Jennison Associates LLC acquired a new position in shares of Travere Therapeutics during the 4th quarter worth approximately $14,222,000. Finally, Wellington Management Group LLP acquired a new stake in Travere Therapeutics in the 4th quarter valued at $583,000.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.